Chile. The Directorate of the Instituto de Salud Pública has stipulated that the labelling for products containing the anorectic agents fenfluramine or dexfenfluramine shall include the following warning with effect from 26 February 1998:

“This medicine must be administered under strict medical supervision because of the risk of damage to the cardiac valves and/or primary pulmonary hypertension.”

[See also Pharmaceuticals Newsletter Nos. 1&2, 3&4, 7&8, 1998 and 9&19, 1997]

Reference: Boletín Informativo sobre Medicamentos Vol.15, No.1, April 1998, Resolution No. 265 of 26 January 1998.